|
市場調查報告書
抗體·藥物複合體(2011年)- 真正大幅進步的到來:技術，相關利益者，研究開發平台分析
Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
|
抗體·藥物複合體(2011年)- 真正大幅進步的到來:技術，相關利益者，研究開發平台分析 是由出版商La Merie Publishing在2011年09月所出版的。
這份英文市場調查報告書包含274 Pages 價格從美金2632起跳。
用本報告提供抗體·藥物複合體能用的交替，相關利益者，研究開發平台，商業的價值，企業簡介等彙整資料，為您概述為以下內容。
第1章 簡稱
第2章 概要
第3章 摘要整理
第4章 用於抗體·藥物複合體的藥物和連接試劑
第5章 用於抗體·藥物複合體的抗體
第6章 抗體·藥物複合體的相關利益者分析
第7章 抗體·藥物複合體的臨床價值
第8章 抗體·藥物複合體的研究開發平台分析
第9章 抗體·藥物複合體的商業價值
第10章 企業簡介
- Abbott
- Aeterna Zentaris
- Allozyne
- Alpha Cancer Technologies
- Ambrx
- Amgen
- Amunix
- Anaphore
- Astellas Pharma (Agensys)
- AstraZeneca (MedImmune)
- Bayer Healthcare Pharmaceuticals
- Biogen Idec
- Biotest
- Bristol-Myers Squibb (Medarex)
- Celldex Therapeutics
- Centrose
- 第一三共
- Genmab
- GlaxoSmithKline
- ImmunoGen
- Immunomedics
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Millennium: The Takeda Oncology Company
- Nerviano Medical Sciences
- Novartis
- Pfizer (Wyeth)
- PharmaMar
- Philogen
- Progenics Pharmaceuticals
- Roche (Genentech)
- Sanofi
- Seattle Genetics
- Spirogen
- Sutro Biopharma
- Synthon (Syntarga)
- Tactic Pharma (Attenuon)
- Wilex (Heidelberg Pharma)
參考
圖表
Abstract
Description
This report “Antibody-Drug Conjugates 2011 - real breakthrough still
to come: A Technology, Stakeholder and R&D Pipeline Analysis” published
in September 2011 provides the most complete compilation of information about
antibody-drug conjugate (ADC) companies, technologies and products in R&D. A
comprehensive analysis of the state of the art and key trends guides the
reader through this complex subject. Stakeholders in the field of
antibody-drug conjugates are analysed and their contribution to the growth ADC
technology and products is assessed. A critical appraisal of the clinical
results of active and discontinued ADC projects and products is provided. ADC
technologies and products are challenged for their commercial value and growth
potential.
Scope of the report
- Drugs and Linkers Used in Antibody-Drug Conjugates
- Antibodies Used in Antibody-Drug Conjugates
- Analysis of Stakeholders in Antibody-Drug Conjugates
- Clinical Value of Antibody-Drug Conjugates
- R&D Pipeline Analysis of Antibody-Drug Conjugates
- Commercial Values of Antibody-Drug Conjugates
- Company Profiles
- Executive ADC Profiles
The recent approval of Seattle Genetics' antibody-drug conjugate Adcetris has
raised great enthusiasm among stakeholders in this field. Accelerated approval
was based on stunning tumor response rates in relapsed Hodgkin' s lymphoma and
anaplastic large cell lymphoma. Analysts expect strong sales of the expensive
therapy. However, the FDA request post-approval studies showing that the high
response rates translate into improved survival and that the clinical benefit
seen in a small study population of 160 patients can be confirmed in a larger
population. Although these data do not have to delivered before 2018,
Genentech will be the next company after Wyeth (now Pfizer) to come up with
survival data of its solid tumor ADC trastuzumab emtansine expected for
2012-2014. So far, only two controlled studies with ADC compounds have been
published: one with Mylotarg failed to show a survival benefit, but t-DM1
pleased with an improved safety profile versus the combination of naked
antibody with systemic chemotherapy
Results of early stage clinical trials of a number of ADC projects promise
anti-tumor activity in hematologic malignancies as well as in solid tumors,
but also dose-limiting toxicities which still narrow the therapeutic window
for the currently used drugs and linkers. Nevertheless, about half of the
currently clinical stage ADC projects entered clinical development within the
last year indicating a high interest in the industry which also is reflected
by the numerous licensing deals of the technology providers with
pharmaceutical and biotech companies. The attrition rate of ADC development
projects so far is well within the rate in oncology, or even better. However,
ADC technologies still can be improved and candidates are emerging but need
more time for validation and maturation.
Features and Benefits
- Understand available drug-linker technologies
- Identify key trends of novel ADC concepts and drug-linker technologies
- Understand the complexity of the chemistry, manufacturing and control of
ADC products and which approaches can taken to reduce it
- Perceive a realistic target profile of current ADC compounds and how it
can be improved;
- Understand which tumor antigens are targeted by ADCs and their role
- See which companies can provide solutions
- Understand the commercial value of ADC technologies and ADC products
Table of Contents
1. Abbreviations
2. Overview
3. Executive Summary
4. Drugs and Linkers Used in Antibody-Drug Conjugates
5. Antibodies Used in Antibody-Drug Conjugates
6. Analysis of Stakeholders in Antibody-Drug Conjugates
7. Clinical Value of Antibody-Drug Conjugates
8. R&D Pipeline Analysis of Antibody-Drug Conjugates
9. Commercial Values of Antibody-Drug Conjugates
10. Company Profiles
- Abbott
- Aeterna Zentaris
- Allozyne
- Alpha Cancer Technologies
- Ambrx
- Amgen
- Amunix
- Anaphore
- Astellas Pharma (Agensys)
- AstraZeneca (MedImmune)
- Bayer Healthcare Pharmaceuticals
- Biogen Idec
- Biotest
- Bristol-Myers Squibb (Medarex)
- Celldex Therapeutics
- Centrose
- Daiichi Sankyo
- Genmab
- GlaxoSmithKline
- ImmunoGen
- Immunomedics
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Millennium: The Takeda Oncology Company
- Nerviano Medical Sciences
- Novartis
- Pfizer (Wyeth)
- PharmaMar
- Philogen
- Progenics Pharmaceuticals
- Roche (Genentech)
- Sanofi
- Seattle Genetics
- Spirogen
- Sutro Biopharma
- Synthon (Syntarga)
- Tactic Pharma (Attenuon)
- Wilex (Heidelberg Pharma)
- References
Tables
- Table 1 Characterization of Antibody-Drug Conjugates
- Table 2 Drugs in Use for Antibody-Drug Conjugates
- Table 3 Seattle Genetics ADC Technology Licensing Agreements
- Table 4 Immunogen ADC Technology Licensing Agreement
- Table 5 Antibody-Drug Conjugates in IND and Clinical Stages
- Table 6 Linkers in Use for Clinical-Stage Antibody-Drug Conjugates
- Table 7 Advantages and Disadvantages of Linkers and Cytotoxic Drugs
- Table 8 Companies Active in R&D of New Cytotoxic Drugs for ADCs
- Table 9 Companies Active in R&D of New Linkers for ADCs
- Table 10 Immunogenicity of Antibody-Drug Conjugates
- Table 11 Number of drug molecules per antibody
- Table 12 Activities of Companies in the ADC Field
- Table 13 Strengths & Weaknesses of Integrated ADC Technology & Product
Companies
- Table 14 Emerging ADC Technology Companies
- Table 15 Immunoconjugate & Alternative ADC Companies
- Table 16 Reasons for Discontinuation of Clinical Stage Antibody-Drug
Conjugates
- Table 21 Main Clinical Trials with T-DM1 in Metastatic Breast Cancer
- Table 18 Clinical Results of phase I/II stage Antibody-Drug Conjugates
- Table 19 Antibody-Drug Conjugates in Non-Clinical Development and
Preclinical R&D
- Table 20 Antibody-Drug Conjugates Discontinued in Clinical Stages
- Table 21 Targets of Antibody-Drug Conjugates
- Table 22 Immunoconjugates with Non-Antibody Targeting Moiety
Executive ADC Profiles
- AEZS-108
- AGS-16M8F
- ASG-5ME
- ASG-22ME
- BAY 79-4620
- BAY 94-9343
- BIIB015
- BT-062
- CR011-vcMMAE
- CR014-vcMAE
- hRS7-SN-38
- IMGN388
- IMGN529
- IMGN853
- IMGN901
- Inotuzumab ozogamicin
- Labetuzumab-SN-38
- LIV-1 ADC
- MDX-1203
- MDX-1204
- MEDI-547
- Milatuzumab-doxorubicin
- MM-302
- PSMA-ADC
- RG7596
- SAR3419
- SAR566658
- SGN-19A
- SGN-35
- SGN-75
- Trastuzumab-DM1
|
